- Home
- RDHL vs SNGX Comparison
RDHL vs SNGX Comparison
Compare RDHL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- SNGX
- Stock Information
- Founded
- RDHL 2009
- SNGX 1987
- Country
- RDHL Israel
- SNGX United States
- Employees
- RDHL N/A
- SNGX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- SNGX Health Care
- Exchange
- RDHL Nasdaq
- SNGX Nasdaq
- Market Cap
- RDHL 3.9M
- SNGX 10.1M
- IPO Year
- RDHL N/A
- SNGX 1987
- Fundamental
- Price
- RDHL $1.50
- SNGX $2.75
- Analyst Decision
- RDHL
- SNGX Strong Buy
- Analyst Count
- RDHL 0
- SNGX 1
- Target Price
- RDHL N/A
- SNGX $6.00
- AVG Volume (30 Days)
- RDHL 88.3K
- SNGX 10.0M
- Earning Date
- RDHL 09-05-2025
- SNGX 11-07-2025
- Dividend Yield
- RDHL N/A
- SNGX N/A
- EPS Growth
- RDHL N/A
- SNGX N/A
- EPS
- RDHL N/A
- SNGX N/A
- Revenue
- RDHL $9,550,000.00
- SNGX N/A
- Revenue This Year
- RDHL $381.91
- SNGX N/A
- Revenue Next Year
- RDHL N/A
- SNGX N/A
- P/E Ratio
- RDHL N/A
- SNGX N/A
- Revenue Growth
- RDHL 157.62
- SNGX N/A
- 52 Week Low
- RDHL $1.06
- SNGX $1.09
- 52 Week High
- RDHL $11.70
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- RDHL 53.60
- SNGX 48.17
- Support Level
- RDHL $1.22
- SNGX $2.58
- Resistance Level
- RDHL $1.60
- SNGX $2.98
- Average True Range (ATR)
- RDHL 0.08
- SNGX 0.21
- MACD
- RDHL 0.04
- SNGX -0.09
- Stochastic Oscillator
- RDHL 73.68
- SNGX 21.79
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).